Evidence map›Paper›PMID 41431636›Full record

ReviewAddiction & health2025

Pulmonary Complications of Substance Abuse: Pathophysiology, Diagnosis, and Management Strategies.

Fariba Shahi, Roya Rafaiee, Niloofar Keikhaei, Seyedeh Hatameh Asadinejad Tahergourabi, Hamid Jomehpour, Hamid Kalalian-Moghaddam, Mohammad Niroumand Sarvandani, Raheleh Rafaiee

Abstract readReview
In one paragraph

Review in Addiction & health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Fariba ShahiDepartment of Clinical Psychology, Science and Research Branch, Islamic Azad University, Tehran, Iran.ORCID https://orcid.org/0009-0001-0338-8130
Roya RafaieeDepartment of Internal Medicine, School of Medicine, Zahedan University of Medical Sciences, Zahedan, Iran.ORCID https://orcid.org/0000-0003-0889-710X
Niloofar KeikhaeiDepartment of Internal Medicine, School of Medicine, Sayyad Shirazi Hospital, Golestan University of Medical Sciences, Gorgan, Iran.ORCID https://orcid.org/0000-0002-7292-8639
Seyedeh Hatameh Asadinejad TahergourabiDepartment of Pulmonary Medicine, Hazrate-Rasoul Akram Hospital, Iran University of Medical Sciences, Tehran, Iran.ORCID https://orcid.org/0009-0008-6790-8685
Hamid JomehpourPsychiatry and Behavioral Sciences Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.ORCID https://orcid.org/0000-0002-7072-9847
Hamid Kalalian-MoghaddamCenter for Health Related Social and Behavioral Sciences Research, Shahroud University of Medical Sciences, Shahroud, Iran.ORCID https://orcid.org/0000-0002-8342-919X
Mohammad Niroumand SarvandaniSocial Development and Health Promotion Research Center, Gonabad University of Medical Sciences, Gonabad, Iran.ORCID https://orcid.org/0000-0001-9790-3908
Raheleh RafaieePsychiatry and Behavioral Sciences Research Center, Addiction Institute, Mazandaran University of Medical Sciences, Sari, Mazandaran, Iran.ORCID https://orcid.org/0000-0003-2796-5868

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Substance abuse significantly impacts pulmonary health, with diverse complications arising from the use of tobacco, alcohol, opioids, and other illicit drugs. These substances can directly damage lung tissue and exacerbate chronic respiratory diseases through mechanisms like oxidative stress, inflammation, and immune dysfunction. This study reviewed current evidence on the prevalence, pathophysiology, and clinical manifestations of pulmonary complications associated with substance abuse. Key findings include the high prevalence of chronic obstructive pulmonary disease among heroin users, the association of cocaine with acute and chronic pulmonary conditions, and the role of alcohol in exacerbating respiratory infections and acute respiratory distress syndrome. The review highlights diagnostic challenges, emphasizing the need for comprehensive clinical assessments, advanced imaging, and biomarker utilization. Additionally, it outlines treatment strategies, including pharmacological interventions, smoking cessation programs, and pulmonary rehabilitation. Recognizing the public health implications, the review advocates preventive measures, harm reduction strategies, and integrated care models to mitigate the burden of substance-related pulmonary diseases.

Indexed as

Illicit drugsPulmonary complicationsRespiratory diseasesSubstance abuse

Identifiers

PMID41431636
PMCPMC12718420

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.